Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study

SIMPLE SUMMARY: Sarcomas are a group of cancers with differing clinical features, some of which require long courses of cytotoxic chemotherapy. Therefore, patients with sarcoma may be at high risk of developing severe COVID-19. The aim of our study was to describe risk factors and clinical outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Michael J., Hennessy, Cassandra, Beeghly, Alicia, French, Benjamin, Shah, Dimpy P., Croessmann, Sarah, Vilar-Compte, Diana, Ruiz-Garcia, Erika, Ingham, Matthew, Schwartz, Gary K., Painter, Corrie A., Chugh, Rashmi, Fecher, Leslie, Park, Cathleen, Zamulko, Olga, Trent, Jonathan C., Subbiah, Vivek, Khaki, Ali Raza, Tachiki, Lisa, Nakasone, Elizabeth S., Loggers, Elizabeth T., Labaki, Chris, Saliby, Renee Maria, McKay, Rana R., Ajmera, Archana, Griffiths, Elizabeth A., Puzanov, Igor, Tap, William D., Hwang, Clara, Tejwani, Sheela, Jhawar, Sachin R., Hayes-Lattin, Brandon, Wulff-Burchfield, Elizabeth, Kasi, Anup, Reuben, Daniel Y., Nagaraj, Gayathri, Joshi, Monika, Polimera, Hyma, Kulkarni, Amit A., Esfahani, Khashayar, Kwon, Daniel H., Paoluzzi, Luca, Bilen, Mehmet A., Durbin, Eric B., Grivas, Petros, Warner, Jeremy L., Davis, Elizabeth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454925/
https://www.ncbi.nlm.nih.gov/pubmed/36077869
http://dx.doi.org/10.3390/cancers14174334
Descripción
Sumario:SIMPLE SUMMARY: Sarcomas are a group of cancers with differing clinical features, some of which require long courses of cytotoxic chemotherapy. Therefore, patients with sarcoma may be at high risk of developing severe COVID-19. The aim of our study was to describe risk factors and clinical outcomes for patients with sarcoma and COVID-19. We show that patients with sarcoma have high rates of complications from COVID-19. Risk factors for more severe COVID-19 included older age, poor performance status, and lung metastases. We also compared 30 day mortality rates to a matched cohort of patients with sarcoma without COVID-19 and found that patients with bone sarcoma may be at higher risk of death from COVID-19 than patients with other sarcoma subtypes. ABSTRACT: Background: Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19. Methods: We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed. Results: of 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity. Conclusions: Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.

Ejemplares similares